A detailed history of Raleigh Capital Management Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Raleigh Capital Management Inc. holds 95 shares of BIIB stock, worth $18,824. This represents 0.01% of its overall portfolio holdings.

Number of Shares
95
Previous 48 97.92%
Holding current value
$18,824
Previous $10,000 120.0%
% of portfolio
0.01%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$190.52 - $236.72 $8,954 - $11,125
47 Added 97.92%
95 $22,000
Q1 2024

May 13, 2024

BUY
$212.02 - $267.71 $3,816 - $4,818
18 Added 60.0%
48 $10,000
Q4 2023

Feb 21, 2024

BUY
$222.59 - $267.94 $1,112 - $1,339
5 Added 20.0%
30 $7,000
Q2 2023

Jul 25, 2023

BUY
$275.25 - $318.06 $6,881 - $7,951
25 New
25 $7,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $28.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Raleigh Capital Management Inc. Portfolio

Follow Raleigh Capital Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raleigh Capital Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raleigh Capital Management Inc. with notifications on news.